Procter & Gamble Health Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹9,152 Cr
- P/E
- 27.46
- ROE
- 61.86%
- PEG
- 1.42
- Price to sales
- 6.39
- Debt to equity
- 0.02
- 52W high / low
- ₹6,918 / ₹4,779
- Sales growth (5Y)
- 0.76%
- EBITDA margin
- 32.51%
- Net profit margin
- 23.32%
- Promoter holding
- 51.82%
- Sales (last year)
- ₹1,433 Cr
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.[1]
Guidance scorecard · Q1 FY27 call
What P & G Health Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ4 FY26 call
10–20%- Confident of continuing the growth momentum driven by Integrated Growth Strategy focusing on Superiority, Productivity, Constructive Disruption, and Organization.
- Expect balanced growth through strong brand fundamentals, superior retail execution, new user acquisition, and product innovations.
- Recorded mid-single digit volume growth in FY26, with innovations contributing early single-digit points of growth.
- Poised for sustained double-digit sales growth, supported by increasing health consciousness and expanding VMS market in India.
- Export business showing strong potential with 3X growth in Nepal and high single-digit growth in Sri Lanka, adding to overall growth prospects.
- E-commerce channel rapidly growing and material, contributing to sales growth alongside traditional retail.
2 more points from P & G Health Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
FlatSee what P & G Health Ltd said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- Continuous investment across the value chain to address evolving consumer and patient needs, including product innovation, communication initiatives, and strengthening go-to-market and supply chain capabilities.
- Investment back into the business in areas such as advertising, demand generation, and superior retail execution while maintaining productivity focus.
- Strategic choice to embed productivity deeply to fund superiority and deliver financial results.
2 more points from P & G Health Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
See what P & G Health Ltd said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
RisingAsk what P & G Health Ltd said on the order book →
Full Q4 FY26 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track P & G Health Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of P & G Health Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of P & G Health Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 321 | 301 | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 | 374 | 370 |
| Expenses + | 241 | 256 | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 | 263 | 235 |
| Operating Profit | 80 | 45 | 89 | 102 | 67 | 48 | 114 | 123 | 81 | 90 | 120 | 110 | 136 |
| OPM % | 25% | 15% | 29% | 33% | 27% | 17% | 36% | 40% | 26% | 27% | 37% | 30% | 37% |
| Other Income + | 5 | 5 | 6 | 5 | 2 | -18 | 3 | 4 | 3 | 4 | 5 | 4 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 6 |
| Profit before tax | 79 | 44 | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 | 109 | 133 |
| Tax % | 25% | 32% | 26% | 28% | 26% | 26% | 26% | 25% | 22% | 25% | 26% | 29% | 29% |
| Net Profit + | 59 | 30 | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 | 78 | 95 |
| EPS in Rs | 35.66 | 17.96 | 39.50 | 43.42 | 28.05 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 |
Financials of P & G Health Ltd
Profit & Loss
Annual income statement trend
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 9m | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 940 | 993 | 698 | 849 | 927 | 1,356 | 1,009 | 1,114 | 1,230 | 1,151 | 934 | 1,408 |
| Expenses + | 855 | 877 | 621 | 701 | 723 | 1,037 | 762 | 846 | 905 | 845 | 616 | 951 |
| Operating Profit | 85 | 116 | 77 | 148 | 204 | 319 | 246 | 268 | 325 | 307 | 319 | 457 |
| OPM % | 9% | 12% | 11% | 17% | 22% | 24% | 24% | 24% | 26% | 27% | 34% | 32% |
| Other Income + | 22 | 24 | 74 | 768 | 48 | 66 | 18 | 13 | 18 | -5 | 10 | 17 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
| Depreciation | 23 | 25 | 19 | 21 | 17 | 29 | 30 | 27 | 28 | 27 | 17 | 24 |
| Profit before tax | 83 | 115 | 132 | 895 | 234 | 355 | 233 | 253 | 314 | 273 | 312 | 450 |
| Tax % | 36% | 31% | 29% | 6% | 32% | 28% | 24% | 24% | 27% | 26% | 25% | 27% |
| Net Profit + | 54 | 79 | 94 | 839 | 159 | 254 | 177 | 193 | 229 | 201 | 234 | 327 |
| EPS in Rs | 32.27 | 47.67 | 56.57 | 505.27 | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 141.22 | 196.94 |
| Dividend Payout % | 23% | 23% | 27% | 87% | 0% | 150% | 122% | 45% | 69% | 215% | 89% | 211% |
Financials of P & G Health Ltd
Balance Sheet
Capital structure and asset base
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 575 | 647 | 717 | 1,524 | 800 | 890 | 687 | 600 | 734 | 522 | 520 | 508 |
| Borrowings + | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 3 | 12 | 10 | 8 | 9 |
| Other Liabilities + | 192 | 215 | 258 | 219 | 250 | 269 | 275 | 269 | 338 | 247 | 250 | 308 |
| Total Liabilities | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 841 |
| Fixed Assets + | 132 | 111 | 115 | 104 | 101 | 101 | 104 | 112 | 144 | 128 | 116 | 102 |
| CWIP | 7 | 30 | 9 | 17 | 11 | 21 | 39 | 41 | 32 | 6 | 11 | 14 |
| Investments | 42 | 28 | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 603 | 711 | 797 | 1,639 | 954 | 1,053 | 843 | 736 | 925 | 660 | 667 | 726 |
| Total Assets | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 841 |
Financials of P & G Health Ltd
Cash Flows
Operating, investing and financing cash movement
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 83 | 107 | 54 | -130 | 235 | 247 | 170 | 236 | 228 | 169 | 338 | |
| Cash from Investing Activity + | -68 | -75 | -48 | 1,270 | 165 | -32 | -26 | -22 | -7 | 10 | 1 | |
| Cash from Financing Activity + | -12 | -15 | -22 | -30 | -883 | -387 | -289 | -98 | -418 | -235 | -344 | |
| Net Cash Flow | 4 | 17 | -16 | 1,109 | -483 | -172 | -145 | 116 | -197 | -56 | -5 | |
| Free Cash Flow | 38 | 75 | 24 | -157 | 212 | 196 | 132 | 198 | 207 | 168 | 323 | |
| CFO/OP | 136% | 138% | 147% | 117% | 106% | 128% | 87% | 100% | 102% | 78% | 97% |
Financials of P & G Health Ltd
Ratios
Working capital efficiency and return ratios
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 49 | 39 | 64 | 28 | 30 | 26 | 22 | 27 | 34 | 27 | 57 | 43 |
| Inventory Days | 140 | 145 | 243 | 154 | 139 | 113 | 138 | 124 | 136 | 120 | 152 | 137 |
| Days Payable | 55 | 67 | 128 | 124 | 106 | 105 | 209 | 185 | 239 | 184 | 239 | 192 |
| Cash Conversion Cycle | 134 | 118 | 179 | 58 | 63 | 34 | -49 | -34 | -69 | -37 | -30 | -13 |
| Working Capital Days | 69 | 52 | 94 | 42 | 22 | 23 | 7 | 17 | 15 | 19 | 48 | 30 |
| ROCE % | 15% | 18% | 16% | 78% | 20% | 29% | 29% | 38% | 45% | 45% | 48% | 84% |
Guidance history
How P & G Health Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY26 call → | 10–20% | Flat | Planned | — | Rising |
| Q4 FY25 call → | 0–10% | Flat | — | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
25 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −10.9% | 48% |
| Last 6 months | +5.7% | 62% |
| Last 3 months | −15.2% | 28% |
The price is 25.3% below its all-time high of ₹7,379.45 (12 Feb 2021). Stocks more than 20% below their peak have their score halved, so 49 became 25.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For P & G Health Ltd: 0.4 × 48 + 0.4 × 62 + 0.2 × 28 = 49, halved to 25 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What P & G Health Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY